Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/94952
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors |
Author: | Yeung, D. Mauro, M. |
Citation: | Hematology online (ASH), 2014; 2014(1):240-243 |
Publisher: | American Society of Hematology |
Issue Date: | 2014 |
ISSN: | 1520-4391 1520-4383 |
Statement of Responsibility: | David T. Yeung, and Michael J. Mauro |
Abstract: | A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 × 10(9)/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response? |
Keywords: | Humans Protein Kinase Inhibitors Prognosis Disease-Free Survival Treatment Outcome Middle Aged Male Leukemia, Myelogenous, Chronic, BCR-ABL Positive Practice Guidelines as Topic |
Rights: | © 2015 by the American Society of Hematology |
DOI: | 10.1182/asheducation-2014.1.240 |
Published version: | http://dx.doi.org/10.1182/asheducation-2014.1.240 |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.